Jaffee, Elizabeth M.

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 3,969

Tumor mutational burden and response rate to PD-1 inhibition

Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 3,230

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019) · Annals of Oncology

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 2,683

Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts

Elyada, E., Bolisetty, M., Laise, P., Flynn, W. F., Courtois, E. T., Burkhart, R. A., Teinor, J. A., Belleau, P., Biffi, G., Lucito, M. S., et al. (2019) · Cancer Discovery

Pancreatic and Hepatic Oncology ResearchPeptidase Inhibition and Analysis

Cited by 2,241

Targeting neoantigens to augment antitumour immunity

Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 997

Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene

Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., Lin, J. C.-H., Palmisano, E., Brune, K., Jaffee, E. M., et al. (2009) · Science

BRCA gene mutations in cancerPancreatic and Hepatic Oncology Research

Cited by 826

Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes –Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer

Le, D. T., Wang-Gillam, A., Picozzi, V., Greten, T. F., Crocenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R. L., et al. (2015) · Journal of Clinical Oncology

Immunotherapy and Immune ResponsesPancreatic and Hepatic Oncology Research

Cited by 611

Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells

Kouo, T., Huang, L., Pucsek, A. B., Cao, M., Solt, S., Armstrong, T., & Jaffee, E. (2015) · Cancer Immunology Research

Galectins and Cancer BiologyCancer Immunotherapy and Biomarkers

Cited by 531

Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia

McAllister, F., Bailey, J. M., Alsina, J., Nirschl, C. J., Sharma, R., Fan, H., Rattigan, Y., Roeser, J. C., Lankapalli, R. H., Zhang, H., et al. (2014) · Cancer Cell

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 405

SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer

Blackford, A., Serrano, O. K., Wolfgang, C. L., Parmigiani, G., Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Eshleman, J. R., et al. (2009) · Clinical Cancer Research

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 371

Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity

Ho, W. J., Zhu, Q., Durham, J., Popovic, A., Xavier, S., Leatherman, J., Mohan, A., Mo, G., Zhang, S., Gross, N., et al. (2021) · Nature Cancer

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 360

Major histocompatibility complex class II‐restricted presentation of a cytosolic antigen by autophagy

Nimmerjahn, F., Milosevic, S., Behrends, U., Jaffee, E. M., Pardoll, D. M., Bornkamm, G. W., & Mautner, J. (2003) · European Journal of Immunology

Immunotherapy and Immune ResponsesAutophagy in Disease and Therapy

Cited by 359

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

Ferris, R. L., Jaffee, E. M., & Ferrone, S. (2010) · Journal of Clinical Oncology

Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and Biomarkers

Cited by 320

Regulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective

Le, D. T., & Jaffee, E. M. (2012) · Cancer Research

T-cell and B-cell ImmunologyImmunotherapy and Immune Responses

Cited by 240

T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma

Hopkins, A. C., Yarchoan, M., Durham, J. N., Yusko, E. C., Rytlewski, J. A., Robins, H. S., Laheru, D. A., Le, D. T., Lutz, E. R., & Jaffee, E. M. (2018) · JCI Insight

Cancer Immunotherapy and BiomarkersPancreatic and Hepatic Oncology Research

Cited by 233

Neoadjuvant Selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer

Byrne, K. T., Betts, C. B., Mick, R., Sivagnanam, S., Bajor, D. L., Laheru, D. A., Chiorean, E. G., O'Hara, M. H., Liudahl, S. M., Newcomb, C., et al. (2021) · Clinical Cancer Research

Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers

Cited by 199

Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade

Stein, J. E., Lipson, E. J., Cottrell, T. R., Forde, P. M., Anders, R. A., Cimino-Mathews, A., Thompson, E. D., Allaf, M. E., Yarchoan, M., Feliciano, J., et al. (2020) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies

Cited by 177

Leukocyte heterogeneity in pancreatic ductal adenocarcinoma: phenotypic and spatial features associated with clinical outcome

Liudahl, S. M., Betts, C. B., Sivagnanam, S., Morales-Oyarvide, V., da Silva, A., Yuan, C., Hwang, S., Grossblatt-Wait, A., Leis, K. R., Larson, W., et al. (2021) · Cancer Discovery

Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers

Cited by 164

De novo DNA methylation by DNA methyltransferase 3a controls early effector CD8 + T-cell fate decisions following activation

Ladle, B. H., Li, K.-P., Phillips, M. J., Pucsek, A. B., Haile, A., Powell, J. D., Jaffee, E. M., Hildeman, D. A., & Gamper, C. J. (2016) · Proceedings of the National Academy of Sciences

T-cell and B-cell ImmunologyEpigenetics and DNA Methylation

Cited by 152

Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

Zhang, S., Yuan, L., Danilova, L., Mo, G., Zhu, Q., Deshpande, A., Bell, A. T. F., Elisseeff, J., Popel, A. S., Anders, R. A., et al. (2023) · Genome Medicine

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 140

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma

Ho, W. J., Danilova, L., Lim, S. J., Verma, R., Xavier, S., Leatherman, J. M., Sztein, M. B., Fertig, E. J., Wang, H., Jaffee, E., et al. (2020) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and Prognosis

Cited by 66

Vaccine therapy for pancreatic cancer

Salman, B., Zhou, D., Jaffee, E. M., Edil, B. H., & Zheng, L. (2013) · OncoImmunology

Immunotherapy and Immune ResponsesPancreatic and Hepatic Oncology Research

Cited by 64

PASS-01: pancreatic adenocarcinoma signature stratification for treatment–01

Knox, J. J., Jaffee, E. M., O'Kane, G. M., Plenker, D., Zhang, A., Ramotar, S., Dodd, A., Prince, R. M., Laheru, D., Yu, K. H., et al. (2022) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 17